Healthcare Reform Can Be Painless

SANTA BARBARA, CA--(Marketwire - November 16, 2009) - While Congress and the rest of the nation turn the battle over healthcare reform into a pro-wrestling-style steel cage death match with enough rhetoric to choke an English professor, at least one expert is looking beyond the bills on the table for a different solution.

According to a lengthy report by legal expert Terry Mix, "The American Healthcare Dilemma" (www.terencemix.com), reorganizing the FDA and its activities could save Americans trillions of dollars over the next decade.

Mix believes that cleaning up FDA miscues and duplicative functions can save consumers serious money in unnecessary healthcare costs, as well as free up some much-needed federal dollars. His chief complaints include:

--  More than 50 percent of all serious adverse reactions to drugs are
    discovered after the drugs are initially marketed (e.g., they are not
    detected during premarket testing).
--  About 2,270,000 patients per year incur hospital costs as a result of
    adverse drug reactions.
--  Another 4,300,000 visit other healthcare providers (physicians,
    hospital outpatient departments and emergency rooms) as a result of adverse
    drug reactions.
--  Approximately 230,000 die each year as a result of an adverse drug
    reaction (105,000 using drugs as directed and 125,000 from not following
    directions) -- the fourth leading cause of death in the United States.
--  The total annual healthcare cost as a consequence of adverse drug
    reactions exceeds a staggering $200 billion -- an amount equal to what is
    spent on Medicaid every year and almost half of what is spent on Medicare.
    

"These costs can be cut in half by fixing everything that is wrong with the FDA and the system of testing drugs," he added. "This would amount to health care savings of at least $100 billion per year -- one trillion dollars over ten years."

About Terry Mix

A graduate of the University of Southern California and Hastings College of Law in San Francisco and a member of the California State Bar since January 4, 1967, he has spent most of his 40-plus years in practice engaged in the subspecialty of drug product liability, litigating against many of the major pharmaceutical companies in the United States.

Contact Information: Contact: Rachel Friedman Rachel@newsandexperts.com